Abstract: The present invention describes a polyamide textile fiber comprising conjugated nanoparticles homogeneously dispersed in the fiber, selected from polyethylene glycol-conjugated platinum nanoparticles, hyaluronic acid-conjugated gold nanoparticles and mixtures thereof. The invention also describes how to obtain it as well as its use in a cosmetic skin treatment as a system for the release of said conjugated nanoparticles.

Abstract: Disclosed are cosmetic compositions and methods for making up keratinous tissue using the compositions, as well as methods of making the compositions. The compositions contain a photoluminescent polymer (PLP) which is an oligomeric polyester synthesized from a multifunctional monomer and a diol, and which has grafted thereon an amino acid or an amino acid derivative. The compositions achieve a colorizing and/or UV-protectant effect when applied to keratinous tissue.

Abstract: An agrichemical-containing composition that exhibits excellent agrichemical efficacy is provided. The agrichemical-containing composition comprises hydroxypropyl cellulose, an agrichemical, an organic solvent having a saturated vapor pressure of 50 mmHg or higher at 25° C., and water. When the composition as a whole is taken as 100 wt %, the content of the organic solvent is 0.02 to 1 wt %, and the weight ratio of the hydroxypropyl cellulose to the organic solvent (hydroxypropyl cellulose/organic solvent) is in a range of 0.1 to 2.

Abstract: A sustained release composition comprising a polymer and manufacturing method thereof. The sustained release composition comprises a polymer, a bioactive agent, and a release rate determined agent, wherein the release rate determined agent is dispersed in the sustained release composition to control the release rate of the bioactive agent. The method comprises providing an oil phase comprising a bioactive agent, a polymer, and a release rate determined agent; providing an aqueous phase comprising a surfactant; mixing the oil phase with the aqueous phase to form the sustained release composition having a controlled release effect.

Abstract: The present invention relates to foamable oil-in-water emulsions containing: A) one or more emulsifiers, at least one of which is a non-ionic emulsifier, B) one or more cotensides, C) one or more oils, D) optionally, one or more polar solubilizers, E) optionally, auxiliary and additive substances, F) one or more surfactants, G) water, H) optionally, water-soluble substances, provided that the water content of the emulsion is ?70% by weight and the concentration of surfactant(s) F) is from 0.01 to less than 10% by weight, each based on the entire emulsion. The invention further relates to a method for producing the oil-water emulsions according to the invention, to foams obtained from these oil-water emulsions, to a method for producing the foams, and to the application of the oil-water emulsions according to the invention and to the foams produced therefrom.

Abstract: Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.

Abstract: Geranylgeranyl-2-propanol compound (GGP) having the following formula I: is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on mitochondria and its activity. In particular, GGP can be used for the treatment of wrinkles, fine lines and visible discontinuities of skin, for the treatment pigmentation disorders.

Abstract: The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors.

Abstract: A silica particle for medical imaging includes a bridged silane fluorescent dye incorporated throughout the particle matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R?O)3Si—R—Si(OR?)3, where R is a fluorescent organic bridging group, and where R? is a methyl or ethyl group) and a tetralkoxysilane (e.g., Si(OR?)4, where R? is a methyl or ethyl group) generates particles of a predetermined size and shape. This leaves the surface of each particle available for further modification to facilitate dispersion of the particle into different media. Hence, a surface modifier may be subsequently bonded onto the particle surface. In some embodiments, poly(ethylene glycol) is selected as the surface modifier to increase dispersion of the silica particle in an aqueous media. In some embodiments, the particle is porous allowing for an additional functionality (e.g., a secondary imaging material, such as magnetic nanoparticles, and/or a pharmaceutical drug) to be loaded within the pores.

Abstract: The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Abstract: Described herein are films comprising a zinc-containing compound and a film-stabilizing ingredient, for use in oral and personal care compositions.

Abstract: The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative. As a result of intensive studies in order to find a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative, it was found that, in a European Phase III clinical trial for tafluprost, one of the 15,15-difluoroprostaglandin F2? derivatives, with patients with open-angle glaucoma or ocular hypertension, tafluprost has actions of growing eyelashes, making eyelashes thicker, and changing the color thereof, that is, has an effect of promoting the growth of hair (eyelashes). Therefore, a 15,15-difluoroprostaglandin F2? derivative is useful as a hair growth promoting agent, and is expected to be useful as an active ingredient of a preventive or therapeutic agent for a disease associated with hair such as alopecia and a hair care product or a hair cosmetic product for regrowing hair, growing hair, increasing hair density, nourishing hair, or the like.

Abstract: Disclosed are terpolymer compositions of lactide, glycolide, and caprolactone and methods of making such polymers with an initiator. Methods of using the terpolymers as a drug delivery platform are also disclosed.

Abstract: A process for preparing a dry substantially pure and/or technical carnitine powder or granulate, from a substantially unpurified starting material containing a carnitine compound.

Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.

Abstract: A bone graft composition includes a biologically-resorbable cement and a plurality of processed bone particles, where each of the bone particles have a shape configured to interconnect with adjacent bone particles. A method for treating a bone defect using the bone graft compositions includes providing the bone graft composition and administering an effective amount of the bone graft composition to a site of a bone defect in a subject. Kits including a biologically-resorbable cement powder and a plurality of processed bone particles are also provided.

Abstract: Disclosed are antiperspirant compositions comprising: a) from 10 to 35 wt. %, based on the total weight of the composition, of antiperspirant active; b) triethyl hexanoin, c) at least one additional non-volatile oil, and d) from 1.5 to 30 wt. %, based on the total weight of composition, of structurant, wherein: the ratio, by weight, of triethylhexanoin to additional non-volatile oil is from 5:1 to 1:2; in combination, triethylhexanoin and additional non-volatile oil provide from 35 to 65% of the total weight of the composition; the composition contains from 0 to 5 wt. % of volatile silicone oil; the composition is anhydrous; and the composition is in the form of a solid or soft solid. Also disclosed are methods of making such stick compositions, and methods of ameliorating perspiration by the topical application of such compositions to the skin.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: Provided are cosmetic compositions comprising acrylate film forming polymers and an surface-treated colorants which exhibit an improved or synergistic reduction in their propensity to transfer or rub of during wear.

Abstract: A biodegradable polymeric hydrogel composition including a component A and component B forming a ?-aminoester linkage such that the linkage results in gelation, wherein component A is water soluble polymer containing acrylate functionality and component B is a water soluble amine functionality useful for medical applications such as such as drug delivery, tissue engineering, and biomaterials and method of preparation thereof.